Low-Intensity Focused Ultrasound Neuromodulation of the Mediodorsal Thalamus for Treatment-Resistant Schizophrenia

Inclusion Criteria: * Subject has an age greater or equal to 21 years old. * Subject has a diagnosis of schizophrenia as determined by a review of medical records, discussion with referring psychiatrist, as well as the Structured Clinical Interview for DSM-5 (SCID-5). * Subject is determined to be treatment-resistant for at least one year prior to Visit 1 as demonstrated by clinical evidence (determined via medical records and referring psychiatrist) of persistent auditory hallucinations and/or delusions that have not responded to treatment with three adequate trials/regimens of antipsychotic medication, as follows: a. Adequate trials of any two different antipsychotic medications, belonging to different classes of at least 12 weeks equivalent to at least 500 mg/day of chlorpromazine within the previous five years. * Subject has a score of at least moderate (4) on two of the three BPRS positive symptoms (conceptual disorganization, hallucinatory behavior, and unusual thought content) at all three Baseline Visits. * Subject must be ambulatory. * Female subjects must be practicing an acceptable method of contraception, postmenopausal, physically incapable of childbearing, or; if practicing an acceptable method of contraception, a negative urine pregnancy test must be confirmed at all three Baseline Visits * Subject has decision-making capacity to provide informed consent, as determined by an independent psychiatrist. Exclusion Criteria: * Subject has a positive urine toxicology screen at any of the three Baseline Visits. * Subject has medical contraindications to the procedure as determined by an internist or primary care physician. * Subject is pregnant or breast-feeding. * Subject has a history of alcohol or substance abuse within the past 6 months. * Subject has a medical illness, comorbid psychiatric illness, and/or abnormal diagnostic finding that would interfere with the completion of the study, confound the results of the study, or pose risk to the patient. * Subject has participated in another investigational drug trial or therapeutic trial within 30 days of Baseline Visit 1. * Subject has a neurologic condition or history of traumatic brain injury associated with loss of consciousness and/or intracranial bleeding. * Subject is considered high suicide risk as screened by the Columbia-Suicide Severity Rating Scale (C-SSRS). * Subject has a defibrillator, pacemaker, or other implants that would interfere with MRI * Subject has significant social factors that greatly interfere with consistent follow up and/or support.